The most important thing to understand about cannabis is that your body was built to respond to it — or more precisely, cannabis happens to activate a biological system that your body already uses to regulate itself. The endocannabinoid system (ECS) is one of the largest neurotransmitter networks in the human body, involved in regulating pain, mood, appetite, memory, immune function, sleep, and reproduction. It was discovered only in 1988, making it one of the most recently identified major physiological systems.
Every human being has an endocannabinoid system. It functions regardless of whether you have ever consumed cannabis. And understanding how it works is the key to understanding why cannabis produces the effects it does — and why those effects vary so dramatically between individuals.
The Three Components
The ECS consists of three elements: receptors, endocannabinoids, and enzymes.
Receptors are proteins embedded in cell membranes throughout the body that respond to cannabinoid molecules. The two primary cannabinoid receptors are CB1 and CB2. CB1 receptors are concentrated in the central nervous system — the brain and spinal cord — with the highest densities in the hippocampus (memory), cerebral cortex (higher thinking), basal ganglia (movement), amygdala (emotion), hypothalamus (appetite and body temperature), and cerebellum (coordination). CB2 receptors are primarily found in the immune system, the peripheral nervous system, and the gastrointestinal tract, though they are also present at lower densities in the brain.
The distribution of these receptors explains why cannabis affects so many different functions simultaneously. When THC binds to CB1 receptors in the hippocampus, it affects memory. When it binds to CB1 receptors in the amygdala, it affects emotional processing. When it binds to CB1 receptors in the hypothalamus, it stimulates appetite. One molecule, many locations, many effects.
Endocannabinoids are molecules produced by your own body that bind to cannabinoid receptors. The two most studied are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Anandamide — named from the Sanskrit word ananda, meaning bliss — was the first endocannabinoid discovered, identified in 1992 by Czech chemist Lumír Hanuš and American pharmacologist William Devane. 2-AG is the most abundant endocannabinoid in the brain and acts as a full agonist at both CB1 and CB2 receptors.
Your body produces endocannabinoids on demand — they are synthesized as needed and broken down quickly, unlike neurotransmitters like serotonin or dopamine which are stored in vesicles for later release. This “synthesize on demand” mechanism makes the ECS a remarkably precise regulatory system.
Enzymes break down endocannabinoids after they have served their signaling function. FAAH (fatty acid amide hydrolase) breaks down anandamide. MAGL (monoacylglycerol lipase) breaks down 2-AG. These enzymes ensure that endocannabinoid signaling is temporary and precisely timed.
How Cannabis Hijacks the System
THC — the primary psychoactive compound in cannabis — produces its effects by mimicking anandamide. THC’s molecular shape allows it to bind to CB1 receptors in the same way anandamide does, but with two critical differences.
First, THC is a partial agonist at CB1 receptors, meaning it activates them less fully than 2-AG but in a less precisely controlled manner than anandamide. Second, THC is not broken down by FAAH as quickly as anandamide is, which means its effects last much longer than natural endocannabinoid signaling.
CBD — the second most common cannabinoid — does not bind directly to CB1 or CB2 receptors with significant affinity. Instead, CBD appears to work through multiple indirect mechanisms: it inhibits FAAH (which increases anandamide levels), modulates serotonin receptors (5-HT1A), acts on TRPV1 vanilloid receptors (involved in pain perception), and may act as a negative allosteric modulator of CB1 receptors, effectively reducing THC’s binding efficiency. This is why CBD is often described as moderating or balancing the effects of THC — a relationship explored in depth in our THC vs. CBD comparison.
Clinical Endocannabinoid Deficiency
In 2001, neurologist Ethan Russo proposed the theory of Clinical Endocannabinoid Deficiency (CED) — the hypothesis that some chronic conditions may result from insufficient endocannabinoid tone. The theory suggests that conditions like migraine, fibromyalgia, and irritable bowel syndrome, which share overlapping symptoms, treatment-resistant profiles, and comorbidity patterns, may reflect an underlying deficiency in endocannabinoid signaling.
Research published between 2016 and 2024 has provided supporting evidence. Patients with chronic migraine show lower circulating anandamide levels than controls. Fibromyalgia patients show altered CB1 receptor expression. IBS patients show polymorphisms in genes encoding endocannabinoid system components.
The theory remains debated, but it has shifted clinical thinking about why some patients respond to cannabinoid therapy when conventional treatments fail — and why the response is often systemic rather than targeted to a single symptom.
Why Individual Responses Vary
The ECS explains the enormous variability in cannabis responses between individuals — a phenomenon also driven by terpene profiles and individual neurochemistry. Genetic variations in CB1 receptor density, FAAH enzyme activity, and endocannabinoid production levels differ from person to person. Someone with naturally low anandamide levels and high CB1 receptor density may experience cannabis very differently from someone with high anandamide levels and lower CB1 density. These receptor-level differences also explain why cannabis tolerance develops at different rates for different people.
Explore the interactive ECS body map below to see where cannabinoid receptors are concentrated, what functions they regulate, and how THC and CBD interact with each receptor type differently. Understanding your own endocannabinoid system is the first step toward understanding your relationship with cannabis.